Clinical trials: Antiviral Treatment
Chronic Hepatitis C
Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial
Data have suggested that consensus interferon (CIFN) has greater antiviral activity in vitro compared with interferon alfa-2a or alfa-2b.
- Trial name
- NCT00211692
- Testing
- consensus interferon (Interferon Alfacon-1) and ribavirin, Consensus Interferon alfa (CIFN) and ribavirin
- Volunteers
- 64 people
- Sponsor
- Minneapolis Veterans Affairs Medical Center
Cytomegalovirus Retinitis, HIV Infections
A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Eyes
To determine whether alternating oral ganciclovir with intravenous ( IV ) ganciclovir can prevent relapse of Cytomegalovirus ( CMV ) retinitis and improve quality of life in AIDS patients.
- Trial name
- NCT00001062
- Testing
- Ganciclovir
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza A, Influenza B
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
This randomized, open-label, multicenter phase 2 trial will assess the safety, efficacy, and pharmacokinetics (PK) of anti-influenza plasma in subjects with influenza A or B.
- Trial name
- IRC002 (NCT01052480)
- Testing
- Anti-Influenza Immune Plasma, Standard Care
- Where
- 35 sites in United States
- Volunteers
- 98 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, Chronic
Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection
Interleukin 29 (IL-29) is a substance that is produced in the body to help fight viral infections. The purpose of this study is to test the safety and antiviral effects of PEG-rIL-29 (a man-made form of IL-29) when it is given…
- Trial name
- NCT00565539
- Testing
- PEGylated recombinant interleukin 29 (PEG-rIL-29)
- Where
- 11 sites in United States, Canada
- Volunteers
- 56 people
- Sponsor
- ZymoGenetics
Herpes Simplex, HIV Infections
A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected Patients
To evaluate the safety and efficacy of oral valacyclovir hydrochloride (256U87) vs. acyclovir in the treatment of recurrent anogenital herpes in HIV-infected patients (CD4 greater than or equal to 100).
- Trial name
- NCT00002000
- Testing
- Valacyclovir hydrochloride, Acyclovir
- Where
- 22 sites in United States
- Sponsor
- Glaxo Wellcome
HIV
TMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With Ritonavir ("TMC114/r") in HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications.
The purpose of this study is to compare the efficacy, safety and tolerability of TMC114/r versus Kaletra (a combination pill of lopinavir and ritonavir, ("lpv/rtv") in HIV-1 infected patients who have never been treated with…
- Trial name
- NCT00258557
- Testing
- LPV/RTV, TMC-114/RTV
- Where
- 89 sites in United States, Argentina and 23 more
- Volunteers
- 692 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hepatocellular Carcinoma
Antiviral Therapy for Patients With Liver Cancer After Surgery
This is a single-center, prospective, observational, real world study designed to evaluate the effects of peginterferon α-2b(pegabin) combined with nucleoside (acid) analogs (entecavir,ETV tenofovir,TDF tenofovir alafenamide,TAF)…
- Trial name
- NCT05466565
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Xiangya Hospital of Central South University
Chronic Hepatitis B Infection
The Changes of Treg Cells Frequency and Function During Antiviral Therapy
Pegylated interferon α-2a(Peg-IFN-α) not only inhibit viral replication, but also play an important role in immune regulation, while Nucleoside analog(ue) drugs only inhibit viral replication.
- Trial name
- NCT03210493
- Testing
- Peginterferon Alfa-2a
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Beijing Ditan Hospital
Hepatitis B
Maternal Antiviral Treatment and Infants Immunoprophylaxis in the Prevention of Mother-to-child Transmission
The effective control of nucleos(t)ide analogues for patients infected with hepatitis B has significantly curbed the horizontal transmission of hepatitis B.
- Trial name
- NCT03977987
- Testing
- nucleos(t)ide analogue
- Where
- China
- Volunteers
- 233 people
- Sponsor
- Huashan Hospital
HCV Infection
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
The primary purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and activity of escalating, multiple, oral doses of GS-5885 in subjects with chronic genotype 1 Hepatitis C Virus (HCV) infection.
- Trial name
- NCT01193478
- Testing
- GS-5885
- Where
- 13 sites in United States
- Volunteers
- 71 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C
Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients
The purpose of this study is to determine the change from baseline in HCV Ribonucleic acid (RNA) on Day 4 following three days of dosing with BMS-929075 in chronically genotype subtype 1a and 1b HCV infected subjects
- Trial name
- NCT01525212
- Testing
- BMS-929075
- Where
- 3 sites in Australia
- Sponsor
- Bristol-Myers Squibb
HIV Infections
INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.
This 2 arm study will assess the efficacy and safety of a new regimen of Fuzeon + optimized background antiretroviral treatment, in Fuzeon-naive HIV-1 infected patients with virological failure.
- Trial name
- NCT00615134
- Testing
- enfuvirtide [Fuzeon], Optimized background ARV therapy
- Where
- 30 sites in France
- Volunteers
- 29 people
- Sponsor
- Hoffmann-La Roche
Pediatric Intensive Care Unit, Pediatric Immuno-hematology Department
Population Pharmacokinetics of Anti-infectives in Critically Ill Children
Concentrations and effects of anti-infectives in critically ill children are unpredictable and the risk of under-exposure may be associated with poor clinical outcomes.
- Trial name
- OPTIMOME (NCT02539407)
- Testing
- Pharmacokinetics
- Where
- France
- Volunteers
- 3,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatitis B, Chronic
A Non-invasive Model to Predict Antiviral Therapy in Gray Zone of Chronic Hepatitis B
Establishment and validation of the non-invasive model to predict antiviral therapy in the gray zone of chronic hepatitis B
- Trial name
- NCT06041022
- Testing
- Exposure factors
- Volunteers
- 1,000 people
- Sponsor
- Qilu Hospital of Shandong University
COVID-19
CovidDB: The Covid-19 Inpatient Database
The aim of the project is to better understand the Covid-19 inpatient course of the disease and to quickly identify the positive experiences in the treatment in order to update guidelines for the treatment and use of medication.
- Trial name
- NCT04344171
- Where
- 9 sites in Germany, Romania
- Volunteers
- 5,000 people
- Sponsor
- ClarData
Leukemia, Leukemia, Myeloid
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
This study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded.
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasms by Histologic Type
- Trial name
- CYNK001AML01 (NCT04310592)
- Testing
- CYNK-001
- Where
- 10 sites in United States
- Volunteers
- 27 people
- Sponsor
- Celularity Incorporated
Chronic Hepatitis B Virus Infection
Antiviral Therapy for Patients With Chronic Hepatitis B Infection
The study aims to demonstrate that antiviral therapy for patients with immune tolerance of CHB. On the basis of the original antiviral therapy of entecavir, further clarify the safety and effectiveness of entecavir combined with…
- Trial name
- NCT05382351
- Testing
- Entecavir, Entecavir combined with Tenofovir Amibufenamide
- Where
- China
- Volunteers
- 238 people
- Sponsor
- Sun Yat-sen University
Hepatitis D
Pegylated Interferon to Treat Chronic Hepatitis D
This study will evaluate the safety and effectiveness of a long-acting form of alpha interferon called pegylated interferon in treating hepatitis D virus (HDV) infection.
- Trial name
- NCT00023322
- Testing
- Peginterferon Alpha-2a
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis C, Fibrosis
Combination Drug Therapy for Patients With Hepatitis C
Hepatitis C is a major cause of liver disease in the United States and leads to cirrhosis of the liver in approximately one-third of patients some of whom will ultimately suffer from liver failure or liver cancer.
- Conditions
- Chronic Hepatitis C, Fibrosis, Hemolytic Anemia
- Trial name
- NCT00001729
- Testing
- Ribavirin
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Cytomegalovirus Infection
CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL")
This is a trial of preemptive therapy vs. prophylaxis for prevention of Cytomegalovirus (CMV) disease in R-D+ liver transplant patients.
- Trial name
- NCT01552369
- Testing
- Valganciclovir
- Where
- 6 sites in United States
- Volunteers
- 205 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)